Product launch

SynergyHealth

Intermediate Healthcare Interviewer-led 7 questions 2 exhibits

A private health insurance administrator in a developing country is adopting Synergy Health’s digital tool to improve claims data quality and cut processing times — how should adoption grow?

← Back to the case library · How growth strategy cases run

The brief

Your client is a private health insurance provider operating in a developing country, SynergyHealth. SynergyHealth leads the market by applying a behavioural approach to healthcare, finding innovative ways to encourage their members to make healthy choices and thereby reducing their likelihood of falling ill.

To date, SynergyHealth has launched several products that incentivize members to engage in exercise, have regular health check-ups, and even rewards them for healthy eating choices. To further round out their view of their member's health and to drive more engagement with health care practitioners, SynergyHealth's Chief Digital Officer is considering developing a Digital Health Portal which would include an electronic health record (EHR) so that doctors can capture and share pertinent patient information with SynergyHealth with patients' consent.

SynergyHealth's Chief Digital Officer has approached our firm for strategic advice on how to best drive adoption of the platform.

Structuring Judgement Creativity Expertise Numeracy Synthesis

Practise SynergyHealth live — with an AI interviewer

Case Ace opens the case, poses the questions one at a time, reveals exhibits at the right moments and scores you against the model answer. Included in the MBB bundle — £40 for everything.

Practise with Case Ace →

or get access to everything →

Related cases

Advanced Luma Therapeutics Luma Therapeutics, a US digital health company, must plan the launch of its FDA-cleared prescription digital therapeutic Intermediate Summit Reach Summit Reach, an indoor climbing-gym operator, must build the launch plan for its new climbing gym. Advanced Linden Therapeutics Linden Therapeutics, a US specialty pharmaceutical company facing a patent cliff, must decide which of three rare-diseas

Loading…